28 unknown, 19 recruiting, 18 completed, 7 not yet recruiting. 47 Phase 2, 15 Not applicable, 7 Phase 1, 4 Phase 3, 1 Early Phase 1.
Follow Locally Advanced Rectal Cancer: new trials by email Literature Review of Locally Advanced Rectal Cancer trials Research Report on Locally Advanced Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal Cancer Serplulimab, Bevacizumab, Oxaliplatin - Locally Advanced Rectal Cancer | Not applicable | Not yet recruiting | Tang-Du Hospital | 48 | 2026-10-15 | 2026-10-13 |
| Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer Nivolumab, HDRBET, Total Mesorectal Excision (TME) - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Dr. Te Vuong | 10 | 2026-10-01 | 2026-10-28 |
| Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer Modified Short-course radiotherapy, Long-course radiotherapy, Oxaliplatin - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Fujian Cancer Hospital | 130 | 2026-08-15 | 2026-10-01 |
| ONCO-RET: Supervised Resistance Training During Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer Strength training program - Locally Advanced Rectal Cancer | Not applicable | Not yet recruiting | Fundacion Arturo Lopez Perez | 15 | 2026-03-09 | 2026-03-05 |
| A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer Camrelizumab - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Chinese PLA General Hospital | 44 | 2026-02-01 | 2026-04-14 |
| A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue Curcumin (BCM-95®) - Rectal Cancer, Locally Advanced Rectal Cancer | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 72 | 2026-01-01 | 2025-11-25 |
| Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients Galenic Immunonutrition Formula - Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer | Not applicable | Recruiting | Fondazione del Piemonte per l'Oncologia | 52 | 2025-10-03 | 2026-04-07 |
| Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) Long-course radiotherapy, Oxaliplatin, Capecitabine - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Fudan University | 138 | 2025-08-28 | 2025-09-02 |
| Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer NALIRI, LCRT, FOLFOX - Locally Advanced Rectal Cancer | Phase 3 | Not yet recruiting | Zhejiang Cancer Hospital | 360 | 2025-07-20 | 2025-07-25 |
| Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) Capecitabine, Camrelizumab, CAPOX - Locally Advanced Rectal Cancer | Phase 2 | Suspended | Hebei Medical University Fourth Hospital | 90 | 2025-07-01 | 2026-07-31 |
| Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. Concurrent Chemoradiotherapy（Radiation + Capecitabine）, irinotecan hydrochloride liposome injection, Oxaliplatin - Locally Advanced Rectal Cancer | Not applicable | Recruiting | Peking University Cancer Hospital & Institute | 68 | 2025-04-01 | 2025-03-25 |
| Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer Ivonescimab (SMT112 or AK112) Injection - Locally Advanced Rectal Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 40 | 2025-01-20 | 2025-01-08 |
| Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer short-course radiotherapy, Ivonescimab, capecitabine - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 45 | 2024-10-16 | 2025-01-31 |
| GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer | Recruiting | Fondazione del Piemonte per l'Oncologia | 110 | 2024-09-23 | 2026-04-06 | |
| MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer PD-1 antibody, Oxaliplatin, Capecitabine - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Fudan University | 46 | 2024-08-13 | 2025-02-21 |
| Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer No intervention - Locally Advanced Rectal Cancer | Unknown | Jing-kun Liu | 100 | 2024-05-15 | 2024-04-19 | |
| Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor, Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor - Locally Advanced Rectal Cancer | Phase 2 | Unknown | Beijing Friendship Hospital | 50 | 2024-04-01 | 2024-03-19 |
| CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer PD-1 inhibitor, Capecitabine, Short-course radiotherapy - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Fudan University | 192 | 2024-03-28 | 2026-04-03 |
| Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision - Locally Advanced Rectal Cancer, Older People | Not applicable | Recruiting | Jules Bordet Institute | 230 | 2024-02-07 | 2026-08-03 |
| Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer node-sparing short-course radiotherapy, Sintilimab, Capecitabine - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Jinhua Central Hospital | 37 | 2024-02-05 | 2026-04-24 |
Showing 20 of 83. Sign in to see all of them.
Rectal Neoplasms (17) · Colorectal Neoplasms (4) · Lung Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenoviridae Infections (1) · Digestive System Neoplasms (1) · Gastrointestinal Neoplasms (1) · Hyperthermia (1) · Infections (1) · Intestinal Neoplasms (1) · Neoplasms (1) · Neoplastic Processes (1) · Pathologic Complete Response (1) · Pathologic Processes (1) · Postoperative Complications (1)
Neoplasms by Site (21) · Neoplasms (20) · Digestive System Diseases (19) · Gastrointestinal Diseases (19) · Intestinal Diseases (19) · Rectal Diseases (19) · Digestive System Neoplasms (18) · Gastrointestinal Neoplasms (18) · Intestinal Neoplasms (18) · Colorectal Neoplasms (15) · Pathological Conditions, Signs and Symptoms (5) · Colonic Diseases (4) · Pathologic Processes (3) · Carcinoma (2) · Carcinoma, Squamous Cell (2)
Capecitabine (29) · Oxaliplatin (19) · Irinotecan (8) · spartalizumab (6) · Fluorouracil (5) · Immune Checkpoint Inhibitors (5) · Radiation (5) · Radiotherapy (5) · tislelizumab (5) · Bevacizumab (4) · Neoadjuvant Therapy (4) · sintilimab (4) · toripalimab (3) · Celecoxib (2) · HMPL-013 (2)
Fudan University (10) · Beijing Friendship Hospital (4) · Zhejiang Cancer Hospital (4) · Yonsei University (3) · First Affiliated Hospital of Zhejiang University (2) · Fondazione del Piemonte per l'Oncologia (2) · Hebei Medical University Fourth Hospital (2) · Institute of Oncology Ljubljana (2) · Oslo University Hospital (2) · St Vincent's University Hospital, Ireland (2) · Sun Yat-sen University (2) · The First Hospital of Jilin University (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · AbbVie (prior sponsor, Abbott) (1) · Aiping Zhou (1)
China (40) · Italy (4) · South Korea (4) · Germany (3) · Ireland (3) · Spain (3) · United Kingdom (3) · United States (3) · Belgium (2) · Norway (2) · Slovenia (2) · Taiwan (2) · Australia (1) · Canada (1) · Chile (1)
Zhen Zhang, MD (4) · Zhen Zhang, M.D, PH.D (3) · Ebbe B Thorgersen, MD PhD (2) · Aiping Zhou, Doctor (1) · Alex Mirnezami, Prof (1) · Alexander Stein (1) · Ali I Shamseddine, M.D. (1) · Benjamin Spieler, MD (1) · Chunkang Yang, MD (1) · Desmond Winter, MD (1) · Dimitri Christoforidis (1) · Dr Brian O'Neill, MD (1) · Eric Van Cutsem, Prof. Dr. (1) · Fengpeng Wu (1)
PMID 19594223, PMID 19735878, PMID 20046768, PMID 20726007, PMID 22067400, PMID 25478898, PMID 28497757, PMID 30041962, PMID 30968152, PMID 31108984, PMID 31217818, PMID 31761724, PMID 32029014, PMID 32264919, PMID 32532291, PMID 32873251, PMID 32891715, PMID 33028346, PMID 33119477, PMID 33725387, PMID 33741467, PMID 34178635, PMID 35033008, PMID 35291966, PMID 37370032, PMID 37699634, PMID 38641773, PMID 38950321, PMID 39003182, PMID 39693793, PMID 39762418, PMID 40439832, PMID 40860797, PMID 40876501, PMID 40899645, PMID 41222702, PMID 41287502, PMID 41648032, PMID 42495710, PMID 42551632
2018 (1)